Edelweiss Mid Cap Fund Regular-Growth
The fund is rated 4.5 stars. The strongest areas were investment selection within each asset type, investment selection within each industry, and balance between returns and downside risk. Higher annual fee of 1.89% and above-average fund size of Rs 18,693.49 crore were minor drawbacks.
This fund has a good track record with Asset Selection/Timing, a good track record with Stock Selection/Timing, a good risk-reward ratio. It is important to note, however, that this fund has a 18693.492 AUM and a 1.89 expense ratio. Considering all these factors, we have rated this fund as 4.5 star.
आमचा स्कोअर दीर्घकालीन कामगिरी, जोखीम आणि सातत्य यांचे वजन करतो — फक्त मागील परतावे नाही.
परतावा
21 Sep 2026 पर्यंत
जोखीम गुणोत्तरे
31 Aug 2026 पर्यंत
पोर्टफोलिओ
31 Aug 2026 पर्यंत
मार्केट-कॅप विभागणी
क्षेत्रनिहाय वाटप
होल्डिंग्स (99)
| होल्डिंग | फंडाचा % | मूल्य | शेअर्स |
|---|---|---|---|
| The Federal Bank Ltd. | 3.73% | ₹742.79 Cr | 2,08,23,817 |
| Multi Commodity Exchange Of India Ltd. | 2.69% | ₹534.37 Cr | 15,71,687 |
| Coforge Ltd. | 2.18% | ₹432.76 Cr | 21,79,829 |
| Solar Industries India Ltd. | 2.06% | ₹410.06 Cr | 2,03,930 |
| Persistent Systems Ltd. | 2.04% | ₹405.56 Cr | 7,24,918 |
| City Union Bank Ltd. | 1.98% | ₹393.12 Cr | 1,71,52,756 |
| BSE Ltd. | 1.97% | ₹392.63 Cr | 11,96,328 |
| Marico Ltd. | 1.94% | ₹385.54 Cr | 47,01,724 |
| Fortis Healthcare Ltd. | 1.91% | ₹379.21 Cr | 41,81,418 |
| Ipca Laboratories Ltd. | 1.82% | ₹362.09 Cr | 18,33,465 |
फंड तपशील
Long term capital growth. Investments predominantly in equity and equity related securities focused on smaller companies (generally, the universe will be the companies constituting the bottom fourth by way of market capitalization of stocks listed on th
The scheme aims to generate long term capital appreciation from a portfolio that is substantially constituted of equity and equity related securities of Mid Cap companies.
Exit load of 1%, if redeemed within 90 days.